SEARCH:   Advanced

Blood, 15 December 2005, Vol. 106, No. 13, pp. 4086-4092. Prepublished online as a Blood First Edition Paper on August 30, 2005; DOI 10.1182/blood-2005-03-1072. This Article Full Text (PDF) Supplemental Figure All Versions of this Article: 2005-03-1072v1 106/13/4086    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Taussig, D. C Articles by Bonnet, D. Search for Related Content PubMed PubMed Citation Articles by Taussig, D. C Articles by Bonnet, D. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 16, 2005 Accepted August 3, 2005 Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia David C Taussig, Daniel J Pearce, Catherine Simpson, Ama Z Rohatiner, Andrew T Lister, Gavin Kelly, Jennifer L Luongo, Gwenn-ael H Danet-Desnoyers, and Dominique Bonnet* Haematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom Division of Haematological Oncology, St Bartholomew's Hospital, London, United Kingdom Fluorescence Activated Cell Sorting Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom Computational Genome Analysis Laboratory, Cancer Research UK, London Research InstituteUniversity of Pennsylvania, School of Medicine, London, United Kingdom Department of Hematology/Oncology, University of Pennsylvania School of Medicine, Philadelphia, USA Haematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom; Department of Hematology/Oncology, University of Pennsylvania School of Medicine, Philadelphia, USA * Corresponding author; email: dominique.bonnet{at}cancer.org.uk. Human hematopoietic stem cells (HSCs) are generally thought to lack the markers expressed by differentiated blood cells, the lineage specific antigens. However, recent work suggests that genes associated with the myeloid lineage are transcribed in mouse HSCs. Here, we explore whether myeloid genes are actually translated in human HSCs. We show that the well-established myeloid markers CD33, CD13 and/or CD123 are expressed on human long term repopulating cells from cord blood and bone marrow. In addition, we demonstrate that NOD/SCID leukemia initiating cells (SL-IC) were restricted to the CD33+ fraction in 11 of 12 acute myeloid leukemia (AML) samples studied, indicating that leukemic stem cells (LSCs) express this antigen. This study changes our view of HSCs and the process of differentiation. Furthermore, based on the phenotypic similarity of HSCs and LSCs, our data provide support for the hypothesis that AML derives from a HSC. Our findings also provide a challenge to contemporary attempts to improve the outcome of AML using myeloid antigen targeted therapies, given the potential for HSC killing. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Therapeutically targeting leukemia stem cells Eyal C. Attar Blood 2005 106: 4021-4022. [Full Text] [PDF] This article has been cited by other articles: Hongling Du and H. S. Taylor Reviews: Stem Cells and Female Reproduction Reproductive Sciences, February 1, 2009; 16(2): 126 - 139. [Abstract] [PDF] D. C. Taussig, F. Miraki-Moud, F. Anjos-Afonso, D. J. Pearce, K. Allen, C. Ridler, D. Lillington, H. Oakervee, J. Cavenagh, S. G. Agrawal, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells Blood, August 1, 2008; 112(3): 568 - 575. [Abstract] [Full Text] [PDF] S. Chumsri, W. Matsui, and A. M Burger Therapeutic Implications of Leukemic Stem Cell Pathways Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 397 - 406. [Abstract] [Full Text] [PDF] C. Dos Santos, C. Demur, V. Bardet, N. Prade-Houdellier, B. Payrastre, and C. Recher A critical role for Lyn in acute myeloid leukemia Blood, February 15, 2008; 111(4): 2269 - 2279. [Abstract] [Full Text] [PDF] B. Argiropoulos, E. Yung, and R. K. Humphries Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis Genes & Dev., November 15, 2007; 21(22): 2845 - 2849. [Full Text] [PDF] S. Chumsri, W. Matsui, and A. M. Burger Therapeutic Implications of Leukemic Stem Cell Pathways Clin. Cancer Res., November 15, 2007; 13(22): 6549 - 6554. [Abstract] [Full Text] [PDF] A. van Rhenen, G. A. M. S. van Dongen, A. Kelder, E. J. Rombouts, N. Feller, B. Moshaver, M. S.-v. Walsum, S. Zweegman, G. J. Ossenkoppele, and G. Jan Schuurhuis The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells Blood, October 1, 2007; 110(7): 2659 - 2666. [Abstract] [Full Text] [PDF] M. A. Venneri, M. D. Palma, M. Ponzoni, F. Pucci, C. Scielzo, E. Zonari, R. Mazzieri, C. Doglioni, and L. Naldini Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer Blood, June 15, 2007; 109(12): 5276 - 5285. [Abstract] [Full Text] [PDF] A. K. Burnett and S. Knapper Targeting Treatment in AML Hematology, January 1, 2007; 2007(1): 429 - 434. [Abstract] [Full Text] [PDF] C. T. Jordan, M. L. Guzman, and M. Noble Cancer stem cells. N. Engl. J. Med., September 21, 2006; 355(12): 1253 - 1261. [Full Text] [PDF] B. I. Sikic Multidrug resistance and stem cells in acute myeloid leukemia. Clin. Cancer Res., June 1, 2006; 12(11): 3231 - 3232. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020